- Home
- AIRI vs LYRA Comparison
AIRI vs LYRA Comparison
Compare AIRI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- LYRA
- Stock Information
- Founded
- AIRI 1979
- LYRA 2005
- Country
- AIRI United States
- LYRA United States
- Employees
- AIRI N/A
- LYRA N/A
- Industry
- AIRI Military/Government/Technical
- LYRA Medical/Dental Instruments
- Sector
- AIRI Industrials
- LYRA Health Care
- Exchange
- AIRI Nasdaq
- LYRA Nasdaq
- Market Cap
- AIRI 13.4M
- LYRA 15.0M
- IPO Year
- AIRI N/A
- LYRA 2020
- Fundamental
- Price
- AIRI $3.38
- LYRA $9.40
- Analyst Decision
- AIRI
- LYRA Buy
- Analyst Count
- AIRI 0
- LYRA 2
- Target Price
- AIRI N/A
- LYRA $16.00
- AVG Volume (30 Days)
- AIRI 38.5K
- LYRA 1.9M
- Earning Date
- AIRI 08-13-2025
- LYRA 08-13-2025
- Dividend Yield
- AIRI N/A
- LYRA N/A
- EPS Growth
- AIRI N/A
- LYRA N/A
- EPS
- AIRI N/A
- LYRA N/A
- Revenue
- AIRI $53,182,000.00
- LYRA $1,185,000.00
- Revenue This Year
- AIRI $5.59
- LYRA N/A
- Revenue Next Year
- AIRI $5.00
- LYRA $1,286.17
- P/E Ratio
- AIRI N/A
- LYRA N/A
- Revenue Growth
- AIRI 0.29
- LYRA N/A
- 52 Week Low
- AIRI $3.00
- LYRA $3.81
- 52 Week High
- AIRI $9.44
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- AIRI 46.11
- LYRA 45.31
- Support Level
- AIRI $3.31
- LYRA $10.15
- Resistance Level
- AIRI $3.72
- LYRA $14.88
- Average True Range (ATR)
- AIRI 0.20
- LYRA 2.03
- MACD
- AIRI -0.01
- LYRA -0.67
- Stochastic Oscillator
- AIRI 14.63
- LYRA 0.42
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.